Your browser doesn't support javascript.
loading
Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.
Gilmore, Sarah A; Tam, Danny; Cheung, Tara L; Snyder, Chelsea; Farand, Julie; Dick, Ryan; Matles, Mike; Feng, Joy Y; Ramirez, Ricardo; Li, Li; Yu, Helen; Xu, Yili; Barnes, Dwight; Czerwieniec, Gregg; Brendza, Katherine M; Appleby, Todd C; Birkus, Gabriel; Willkom, Madeleine; Kobayashi, Tetsuya; Paoli, Eric; Labelle, Marc; Boesen, Thomas; Tay, Chin H; Delaney, William E; Notte, Gregory T; Schmitz, Uli; Feierbach, Becket.
Afiliação
  • Gilmore SA; Gilead Sciences, Inc., Foster City, California, United States America.
  • Tam D; Gilead Sciences, Inc., Foster City, California, United States America.
  • Cheung TL; Gilead Sciences, Inc., Foster City, California, United States America.
  • Snyder C; Gilead Sciences, Inc., Foster City, California, United States America.
  • Farand J; Gilead Sciences, Inc., Foster City, California, United States America.
  • Dick R; Gilead Sciences, Inc., Foster City, California, United States America.
  • Matles M; Gilead Sciences, Inc., Foster City, California, United States America.
  • Feng JY; Gilead Sciences, Inc., Foster City, California, United States America.
  • Ramirez R; Gilead Sciences, Inc., Foster City, California, United States America.
  • Li L; Gilead Sciences, Inc., Foster City, California, United States America.
  • Yu H; Gilead Sciences, Inc., Foster City, California, United States America.
  • Xu Y; Gilead Sciences, Inc., Foster City, California, United States America.
  • Barnes D; Gilead Sciences, Inc., Foster City, California, United States America.
  • Czerwieniec G; Gilead Sciences, Inc., Foster City, California, United States America.
  • Brendza KM; Gilead Sciences, Inc., Foster City, California, United States America.
  • Appleby TC; Gilead Sciences, Inc., Foster City, California, United States America.
  • Birkus G; Gilead Sciences, Inc., Foster City, California, United States America.
  • Willkom M; Gilead Sciences, Inc., Foster City, California, United States America.
  • Kobayashi T; Gilead Sciences, Inc., Foster City, California, United States America.
  • Paoli E; Gilead Sciences, Inc., Foster City, California, United States America.
  • Labelle M; EpiTherapeutics ApS, Copenhagen, Denmark.
  • Boesen T; EpiTherapeutics ApS, Copenhagen, Denmark.
  • Tay CH; Novo Nordisk A/S, Bagsvaerd, Denmark.
  • Delaney WE; Gilead Sciences, Inc., Foster City, California, United States America.
  • Notte GT; Gilead Sciences, Inc., Foster City, California, United States America.
  • Schmitz U; Gilead Sciences, Inc., Foster City, California, United States America.
  • Feierbach B; Gilead Sciences, Inc., Foster City, California, United States America.
PLoS One ; 17(12): e0271145, 2022.
Article em En | MEDLINE | ID: mdl-36477212
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus da Hepatite B / Hepatite B Crônica Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus da Hepatite B / Hepatite B Crônica Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article